Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.1.119

Hand-Foot syndrome induced by sorafenib, a multitargeted tyrosine kinase inhibitor, in a patient with advanced renal cell carcinoma  

Lee, Seung Hyun (Department of Pediatrics, Research Institute of Clinical Medicine School of Medicine, Chonbuk National University)
Noh, Sung Hun (Department of Pediatrics, Research Institute of Clinical Medicine School of Medicine, Chonbuk National University)
Kim, Sun Young (Department of Pediatrics, Research Institute of Clinical Medicine School of Medicine, Chonbuk National University)
Jang, Kyu Yun (Department of Pathology, Research Institute of Clinical Medicine School of Medicine, Chonbuk National University)
Hwang, Pyoung Han (Department of Pediatrics, Research Institute of Clinical Medicine School of Medicine, Chonbuk National University)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.1, 2009 , pp. 119-123 More about this Journal
Abstract
Renal cell carcinoma (RCC) arising from epithelial cells of the renal tubules is a highly aggressive and malignant tumor in all ages; however, it rarely occurs in children. the standard treatment for RCC is radical nephrectomy with lymph node dissection when the tumor is localized and can be completely resected. Adjuvant chemotherapy, radiotherapy, and immunotherapy are used for pediatric patients with advanced RCC involving lymph nodes or metastatic lesions. Sorafenib is an oral, multikinase inhibitor that has recently been approved for use in metastatic RCC. Common toxicities that have been reported include dermatologic changes such as rash or desquamation and hand-foot skin reaction, diarrhea, fatigue, alopecia, and hypertension. In particular, hand-foot syndrome (HFS) an erythematous skin lesion of the palms and solesis most often caused by cytostatic chemotherapeutic agents. In this report, we have studied a 14-year-old female patient with hand-foot syndrome that occurred in association with sorafenib for the treatment of metastatic RCC. Furthermore, this case demonstrates that reversal of complications can be achieved by discontinuing the drug and intervention with topical steroids, vitamin E, and high-dose pyridoxine.
Keywords
Hand-Foot syndrome (HFS); Sorafenib; Renal cell carcinoma;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003;4:385-90   DOI   ScienceOn
2 Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythroydysesthesia syndrome. Ann Intern Med 1984;101: 798-800   PUBMED   ScienceOn
3 Banfield GK, Crate ID, Griffiths CL. Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. JR Soc Med 1995;88:356-7   ScienceOn
4 Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-24   DOI   PUBMED   ScienceOn
5 Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar- plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004;94:320-4   DOI   ScienceOn
6 Kumar S, Carr T, Marsden HB, Morris-Jones PH. Study of childhood renal tumors using peroxidase conjugated lectins. J Clin Pathol 1986;39:736-41   DOI   PUBMED
7 Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63   DOI   PUBMED
8 Babhulkar SS, Pande K, Babhulkar S. The hand-foot syndrome in sickle cell haemoglobinopathy. J Bone Joint Surg Br 1995;77:310-2
9 Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine. Eur J Oncol Nurs 2004;8: 531-40   DOI
10 Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26:753-62   PUBMED   ScienceOn
11 Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-6   DOI   ScienceOn
12 Zhao WP, Gnarra JR, Liu S. Renal cell carcinoma: Cytogenetic analysis of tumors and cell lines. Cancer Genet Cytogenet 1995;82:128-39   DOI   ScienceOn
13 Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of HFS in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Investigation 2002;20:3-10   DOI   ScienceOn
14 Gerbrecht BM. Current Canadian experience with capecitabine. Cancer Nursing 2003;26;161-7   DOI   PUBMED   ScienceOn
15 Chin SF, Tchen N, Oza AM, Moore MJ, Warr D, Siu LL. Use of "bag balm" as topical treatment of palmar plantar erythrodysesthesia syndrome in patients receiving selected chemotherapeutic agents. Proceedings of the American Society of Clinical Oncology 2001 May 12-15; San Francisco, CA. (abstract 1632)
16 Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006;18: 615-21   DOI   ScienceOn
17 Lee SD, Kim HJ, Hwang SJ, Kim YJ, Nam SH, Kim BS. Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report. Korean J Intern Med. 2007;22:109-112   DOI   ScienceOn
18 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75   DOI   ScienceOn
19 Morabito A. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006;11:753-64   DOI   ScienceOn
20 Indolfi P, Terenziani M, Casale F, Carli M, Bisogno G, Schiavetti A, et al. Renal cell carcinoma in children: a clinicopathologic study. J Clin Oncol 2003;21:530-5   DOI   ScienceOn